Using oral ziprasidone effectively: The food effect and dose-response

Advances in Therapy

Volumn 26, Issue 8, 2009, Pages 739-748

  Citrome, Leslie ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Dosing; Food; Schizophrenia; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; LORAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADJUVANT THERAPY; ANXIETY DISORDER; AREA UNDER THE CURVE; BIPOLAR DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FOOD; FOOD DRUG INTERACTION; HUMAN; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; ORTHOSTATIC HYPOTENSION; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QT PROLONGATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; ENERGY INTAKE; FOOD-DRUG INTERACTIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTESTINAL ABSORPTION; PIPERAZINES; SAFETY; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME;

EID: 73449097085     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0055-0     Document Type: Review

References (35)

1. W.M. Greenberg L. Citrome 2007 Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials CNS Drug Rev 13 137 177 17627670 10.1111/j.1527-3458.2007.00008.x 1:CAS:528:DC%2BD2sXpsVCltb4%3D (Pubitemid 47052346)
2. Pfizer, Inc. US Geodon (ziprasidone HCl) and Geodon (ziprasidone mesylate) for injection, LAB-0272-3.0 [package insert]. June 2008. Available at: www.pfizer.com/files/products/uspi-geodon.pdf. Accessed June 1, 2009.
3. D. Taylor 2003 Ziprasidone in the management of schizophrenia CNS Drugs 17 423 430 12697001 10.2165/00023210-200317060-00004 1:CAS:528: DC%2BD3sXksVahu7c%3D (Pubitemid 36560704)
4. J.M. Davis N. Chen I.D. Glick 2003 A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 60 553 564 12796218 10.1001/archpsyc.60.6.553 1:CAS:528:DC%2BD3sXltlKhtrc%3D (Pubitemid 36682312)
5. S. Leucht K. Komossa C. Rummel-Kluge 2009 A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia Am J Psychiatry 166 152 163 19015230 10.1176/appi.ajp.2008. 08030368
6. J. Volavka L. Citrome 2009 Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making Expert Opin Pharmacother 10 1917 1928 19558339 10.1517/14656560903061309 1:CAS:528:DC%2BD1MXoslaqtLs%3D
7. B.A. Hamelin S. Allard L. Laplante 1998 The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone Pharmacotherapy 18 9 15 9469675 1:CAS:528:DyaK1cXpt1ymuw%3D%3D
8. J.J. Miceli P. Glue J. Alderman K. Wilner 2007 The effect of food on the absorption of oral ziprasidone Psychopharmacol Bull 40 58 68 18007569
9. K. Gandelman J.A. Alderman P. Glue 2009 The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, cross-over trial J Clin Psychiatry 70 58 62 19026256 10.4088/JCP.08m04104 1:CAS:528:DC%2BD1MXivVGkt7Y%3D
10. Vreeland B, Toto AM, Sakowitz M. Solutions for Wellness. 3rd edition. Indianapolis, IN: Eli Lilly and Co; 2008.
11. M.D. Chermá M. Reis S. Hägg J. Ahlner F. Bengtsson 2008 Therapeutic drug monitoring of ziprasidone in a clinical treatment setting Ther Drug Monit 30 682 688 18824954 10.1097/FTD.0b013e31818ac8ba 1:CAS:528: DC%2BD1cXhsVKnt73O
12. L. Citrome C. Reist L. Palmer 2009 Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder Schizophr Res 108 238 244 19106035 10.1016/j.schres.2008.11.017
13. L. Citrome A. Jaffe J. Levine 2005 Dosing of second-generation antipsychotic medication in a state hospital system J Clin Psychopharmacol 25 388 391 16012286 10.1097/01.jcp.0000169623.30196.b9 (Pubitemid 41060263)
14. L. Citrome A. Jaffe J. Levine 2007 The ups and downs of dosing second-generation antipsychotics Psychiatr Serv 58 11 17215406 10.1176/appi.ps.58.1.11
15. L. Citrome A. Jaffe J. Levine 2009 How dosing of ziprasidone in a state hospital system differs from product labeling J Clin Psychiatry 70 975 982 19653974 10.4088/JCP.08m04531
16. Citrome L, Reist C, Palmer L, et al. Impact of real-world ziprasidone dosing on treatment discontinuation rates in subjects with schizophrenia or bipolar disorder. Poster presentation NR6-105 presented at: 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC.
17. C.D. Mullins F.T. Shaya J.M. Zito N. Obeidat J. Naradzay D.J. Harrison 2006 Effect of initial ziprasidone dose on treatment persistence in schizophrenia Schizophr Res 83 277 284 16545945 10.1016/j.schres.2006.01.013
18. A.T. Joyce D.J. Harrison A.D. Loebel C.T. Carter D.A. Ollendorf 2006 Effect of initial ziprasidone dose on length of therapy in schizophrenia Schizophr Res 83 285 292 16545543 10.1016/j.schres.2006.01.009
19. L. Citrome R. Yang P. Glue O.N. Karayal 2009 Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials Schizophr Res 111 39 45 19375893 10.1016/j.schres.2009.03.009
20. J.M. Davis N. Chen 2004 Dose response and dose equivalence of antipsychotics J Clin Psychopharmacol 24 192 208 15206667 10.1097/01.jcp. 0000117422.05703.ae 1:CAS:528:DC%2BD2cXjslSit7s%3D (Pubitemid 38380844)
21. D. Mamo S. Kapur C.M. Shammi 2004 A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone Am J Psychiatry 161 818 825 15121646 10.1176/appi.ajp.161.5.818 (Pubitemid 38625334)
22. S. Kapur G. Remington 2001 Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient Biol Psychiatry 50 873 883 11743942 10.1016/S0006-3223(01)01251-3 1:CAS:528:DC%2BD3MXovFyqsrk%3D (Pubitemid 34020700)
23. L. Citrome 2008 Quetiapine: dose-response relationship in schizophrenia CNS Drugs 22 69 72 10.2165/00023210-200822010-00005 1:CAS:528: DC%2BD1cXhs1agurw%3D
24. P.J. Weiden D.G. Daniel G. Simpson S.J. Romano 2003 Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone J Clin Psychopharmacol 23 595 600 14624190 10.1097/01.jcp. 0000095347.32154.08 1:CAS:528:DC%2BD3sXptVCntb8%3D (Pubitemid 37443191)
25. P.J. Weiden G.M. Simpson S.G. Potkin R.L. O'sullivan 2003 Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia J Clin Psychiatry 64 580 588 12755663 1:CAS:528: DC%2BD3sXkslOis7g%3D
26. T.S. Stroup J.A. Lieberman J.P. McEvoy 2006 Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic Am J Psychiatry 163 611 622 16585435 10.1176/appi.ajp.163.4.611 (Pubitemid 44464570)
27. J.A. Lieberman T.S. Stroup J.P. McEvoy 2005 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209 1223 16172203 10.1056/NEJMoa051688 1:CAS:528:DC%2BD2MXhtVeltL%2FN (Pubitemid 41345943)
28. L. Citrome 2007 The effectiveness criterion: balancing efficacy against the risks of weight gain J Clin Psychiatry 68suppl.12 12 17
29. P.J. Weiden N. Iqbal A.J. Mendelowitz R. Tandon D.L. Zimbroff R. Ross 2002 Best clinical practice with ziprasidone: update after one year of experience J Psychiatr Pract 8 81 97 15985861 10.1097/00131746-200203000-00004
30. D.L. Sackett W.M. Rosenberg J.A. Gray R.B. Haynes W.S. Richardson 1996 Evidence based medicine: what it is and what it isn't BMJ 312 71 72 8555924 1:STN:280:DyaK287ktF2itw%3D%3D
31. L. Citrome T.A. Ketter 2009 Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions Int J Clin Pract 63 353 359 19222621 10.1111/j.1742-1241.2009.02014.x 1:STN:280:DC%2BD1M7ltlSqsQ%3D%3D
32. L. Citrome 2007 Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety J Clin Psychiatry 68 1876 1885 18162018 10.4088/JCP.v68n1207 1:CAS:528: DC%2BD1cXhtlersL4%3D
33. S. Brook J.V. Lucey K.P. Gunn 2000 Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis J Clin Psychiatry 61 933 941 11206599 1:CAS:528:DC%2BD3MXhtVChtrk%3D (Pubitemid 32058009)
34. S. Brook J. Walden I. Benattia C.O. Siu S.J. Romano 2005 Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study Psychopharmacology (Berl) 178 514 523 10.1007/s00213-004-2082-5 1:CAS:528:DC%2BD2MXit1amtLo%3D (Pubitemid 40486992)
35. D.G. Daniel D.L. Zimbroff R.H. Swift E.P. Harrigan 2004 The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy Int Clin Psychopharmacol 19 9 15 15101564 10.1097/00004850- 200401000-00002 (Pubitemid 38114618)